Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

Colaboración

Año: 2015

Rivera, F; Massuti, B; Salcedo, M; Sastre, J; Galan, JM; Valladares-Ayerbes, M; Serrano, R; de Paredes, MLG; Manzano, JL; Galan, M; Alsina, M; Izquierdo, ALY; Lopez, C; Diaz-Rubio, E; Conde, V; Reboredo, M; Cano, MT; Pachon, V; Aranda, E

Título: CANCER CHEMOTHERAPY AND PHARMACOLOGY

• Q2